Cohort of Women Living With HIV-1 and Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide

Study design This observational study is designed as a multicentric retrospective cohort study conducted in two complementary parts to evaluate B/F/TAF use in pregnant women with HIV-1: * Part 1: encompasses a descriptive analysis examining B/F/TAF utilization patterns among women who received the regimen for at least 30 days during pregnancies with estimated conception date between January 1st 2018 and March 1st 2024. This phase will document treatment initiation patterns, switching behaviors, and comprehensive demographic and clinical characteristics without conducting comparative analyses of effectiveness or safety outcomes. * Part 2: focuses specifically on women who were receiving B/F/TAF before conception and demonstrated viral suppression during their first trimester of pregnancy. This cohort includes women who either maintained B/F/TAF through delivery or switched to alternative regimens. Data collection spans across multiple hospitals, enabling a thorough evaluation of viral, pregnancy and neonatal outcomes in real world setting. Population This retrospective observational cohort will be conducted at HIV treatment centers and specialized obstetric units across six countries: Canada, France, Germany, Italy, Spain, and Portugal. The study is structured in two distinct parts with specific eligibility criteria.